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follow-up among elderly patients hospitalized with HF. 9 Some experimental studies have demonstrated the adverse effects of furosemide in HF models. 10, 11 This may be explained by the fact that loop diuretics activate the RAS and sympathetic nerve system, resulting in the poor prognosis in patients given loop diuretics. 10-12 Diuretics are certainly essential in most patients with CHF to minimize symptoms related to congestion and therefore should not be withdrawn. However, the use of a long-acting rather than a short-acting loop diuretic may well provide a better prognosis in patients with CHF. Yoshida et al reported that the administration of azosemide, a long-acting loop diuretic, improved the mortality rate in a hypertensive HF model. 13 However, there has been no randomized clinical trial of loop diuretics in patients with CHF. Thus, we designed a multicenter prospective study, J-MELODIC (Japanese Multicenter Evaluation of LOng-versus short-acting Diuretics In Congestive heart failure) to obtain clinical evidence of the effects of diuretics in HF patients. 14 This is the first prospective randomized study of the effect of long-term administration of a long-acting vs. a short-acting diuretics on the prognosis in patients with CHF.
Methods

Patients
The design of the J-MELODIC study has been published in detail. 14 The trial was approved by each center's ethics committee and all patients provided written informed consent. Eligibility criteria were as follows: 20 years or older; clinical diagnosis of HF based on a slight modification of the Framingham criteria 15 as previously described 16 within 6 months before study entry; New York Heart Association (NYHA) functional class II or III symptoms; loop diuretic(s) user; and no change in baseline therapy or symptoms of HF within 1 month.
Key exclusion criteria were: uncontrolled diabetes mellitus; uncontrolled hypertension; current symptomatic hypotension; serum creatinine >2.5 mg/dl; acute coronary syndrome; implantable cardiac defibrillator; hemodynamically significant left ventricular outflow tract obstruction; acute myocardial infarction within the past 3 months; percutaneous coronary intervention or open heart surgery within the past 3 months; any change in cardiovascular drug therapy within the month prior to randomization; requirement for intravenous inotropes; and any serious non-cardiovascular disease including malignancy.
Study Procedure
The study used a multicenter, prospective, randomized, open, blinded endpoint (PROBE) design. After screening for eligibility and obtaining written informed consent, patients were randomized to either azosemide or furosemide treatment in a 1:1 ratio. In any arm, patients were treated with standard therapy including digitalis, mineralocorticoid receptor blockers, angiotensin-converting enzyme inhibitors, angiotensin II type 1 receptor blockers, β-blockers, and calcium-channel blockers. Patients discontinued taking any previous loop diuretic(s) and were directly rolled over to one of the 2 arms with either azosemide 30-60 mg/day or furosemide 20-40 mg/day, without a placebo run-in period. We considered 40 mg furosemide to be equivalent to approximately 60 mg azosemide, based on the result of a previous clinical pharmacology study. 17 The dose of each diuretic was appropriately adjusted within 8 weeks according to the symptoms of each patient, and patients were maintained for the rest of the study. When it was difficult to stabilize symptoms of HF, azosemide was increased up to 120 mg/day, and furosemide was increased up to 80 mg/day. Diuretics other than furosemide, azosemide, thiazides and mineralocorticoid inhibitors were not allowed to be taken.
Thereafter, patients were reviewed every 2-8 weeks. The planned minimum follow-up period for each patient was 2 years, and electrocardiography, echocardiography, chest X-ray and blood sampling were conducted at study entry and every 12 months after the randomization.
Study Endpoints
The primary endpoint was a composite of cardiovascular death and unplanned admission to hospital for congestive HF. Cardiovascular death was defined as death from worsening of congestive HF, coronary artery disease, cardiac arrest, cardiac arrhythmia, myocardial infarction, stroke, or sudden death. The secondary endpoints were: all-cause mortality; worsening of the symptoms (defined as either a decrease by ≥1 Mets in the Specific Activity Scale questionnaire score or an increase by ≥I class in the NYHA functional class for at least 3 months as compared with baseline); an increase in brain natriuretic peptide (BNP) by ≥30% of the value at randomization in patients with BNP ≥200 pg/ml at randomization; unplanned admission to hospital for congestive HF, or a need for modification of the treatment for HF (changes in oral medicine for at least 1 month or the addition of intravenous drug(s) for at least 4 h). Hospitalization was defined as care at an acute hospital lasting for at least 24 h. Hospitalization for HF required documentation that worsening HF was the principal reason for admission. Patients who discontinued treatment continued to be followed for events. Endpoints were assessed by the independent endpoint committee for whom the allocated group was blinded to all the committee members.
Statistical Analysis
Sample Size Determination The short-acting loop diuretics, furosemide, has produced data of a 2-year incidence of the Data are mean±standard deviation, median (25 percentile, 75 percentile) or patients number (%). NYHA, New York Heart Association; CTR, cardiothoracic ratio; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; LVEF, left ventricular ejection fraction; LVDd, left ventricular end-diastolic dimension; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; Hb, hemoglobin; BNP, brain natriuretic peptide; NE, norepinephrine; AF, atrial fibrillation; AFL, atrial flutter; HF, heart failure; DCM, dilated cardiomyopathy; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin type 1 receptor blocker. MASUYAMA T et al.
primary endpoint of 35%, whereas the 2-year incidence with the use of the long-acting loop diuretics, torasemide, was demonstrated to be 15%. 18 It suggests that the hazard ratio (HR) of azosemide might be 0.38 against furosemide. However, the 2-year incidence of death and hospitalization for HF in Japanese patients who were treated with standard therapy was reported to be 15.3% for 52 weeks. 19 Therefore, it was assumed to be 25% in furosemide and the HR was conservatively set at 0.5. Assuming a 2-year recruitment and a maximum 4-year follow-up, a total of 132 per group was required to detect a statistical significance between groups with the use of a log-rank test, with a power of 80% under the method by Lakatos and Lan. 20 Considering a small portion of attritions, we ended up with a total of 160 per group. Analyses Values are expressed as mean ± standard deviation (SD). Differences between groups were assessed with the χ2 test for categorical data. Differences in continuous variables between groups were assessed with unpaired Student's t-tests when normally distributed, and with the Wilcoxon rank-sum test when not normally distributed. Cumulative event-free curves were constructed by means of Kaplan-Meier methods, and differences between treatment groups were evaluated with the use of log-rank tests. The Cox proportional hazards regression model was used to examine the effect of treatment in the presence of prespecified covariates. All analyses were conducted in accordance with the intention-to-treat principle. If contact could not be made at the trial cutoff date, the data were censored in the analysis at the time of the last contact (Analysis A). We also performed another analysis by censoring the data when patients were lost to follow-up or discontinued the intervention (Analysis B). Proportions such as worsening BNP and symptoms were compared with either the chi-square test or Fisher's exact test. Statistical significance was defined by 2-sided 5% and the analyses were performed by SAS statistical software version 9.1.
Results
Patients
From June 2, 2006 to August 31, 2008, a total of 320 patients underwent randomization at 15 sites in Japan. Of these patients, 160 were assigned to receive furosemide and 160 to receive azosemide (Figure 1) . The mean age of all patients was 71±11 years (±SD); 39% were female and 11% were in NYHA class III. Median left ventricular ejection fraction (EF) was 51%. The etiology of HF was ischemic heart disease (33%), dilated cardiomyopathy (22%), and others (45%). The 2 treatment groups had similar characteristics at study entry ( Table 1) .
Study Drug Administration and Follow-up 3 patients in the furosemide group and 2 patients in the azosemide group did not start the study medication. At the study's cutoff date, the study drug had been discontinued in 20 patients (12.5%) receiving furosemide and 25 patients (15.6%) receiving azosemide. At the cutoff date, 5 patients (3.1%) in the furosemide group and 3 patients (1.9%) in the azosemide group were lost to follow-up (Figure 1) . Clinical and laboratory parameters 2 years after randomization were similar in the 2 groups ( Table 2) . When the data were censored in the analysis at the time of the last contact (Analysis A), the median duration of follow-up among all patients was 35.2 months, with 913 patient-years of follow-up. When the data were censored for patients were lost to follow-up or discontinuing the intervention (Analysis B), the median duration of follow-up was 35.1 months, with 883 patient-years of follow-up.
Study Endpoints
When we censored the data for patients lost to follow-up only, the composite of cardiovascular death and unplanned admission to hospital for congestive HF (primary endpoint) occurred in 23 patients in the azosemide group and 34 patients in the furosemide group (Figure 2A, Table 3 ). The HR for the primary endpoint in the azosemide group, as compared to the furosemide group, was 0.55 (95% confidence interval [CI] 0.32-0.95: P=0.03). It was consistent across all subgroup analysis (Figure 3) . Among the secondary endpoints, unplanned admission to hospital for congestive HF or the need for modification of the treatment for HF occurred in 26 patients in the azosemide group and 36 patients in the furosemide group (HR 0.60, 95%CI 0.36-0.99: P=0.048) ( Figure 2B, Table 3 ). Allcause mortality was recorded for 17 patients in the azosemide group and for 17 patients in the furosemide group (no difference between the 2 groups) ( Figure 2C, Table 3 ).
When we censored the data for patients lost to follow-up or discontinuing the intervention, the value for the primary out- Table 1 . Long-Acting Loop Diuretic in Congestive HF Figure 2 . Cumulative Kaplan-Meier estimates of the rates of the primary endpoint and other endpoints, according to study group. The hazard ratios for azosemide vs. furosemide are shown for cardiovascular death or unplanned hospitalization for congestive heart failure (the primary endpoint) (A), unplanned hospitalization or modification of treatment for congestive heart failure (B), and death from any cause (C). MASUYAMA T et al.
come was lower in the azosemide group than in the frosemide group (18 vs. 32, P=0.01) ( Table 4) . Among the secondary endpoints, unplanned admission to hospital for congestive HF or the need for modification of the treatment for HF occurred less frequently in the azosemide group than in the furosemide group (22 vs. 35, P=0.02) ( Table 4) . Worsening of symptoms occurred in 29 patients in the azosemide group and in 34 patients in the furosemide group at 1 year after randomization (P=0.67) and in 34 patients in the azosemide group and 33 patients in the furosemide group at 2 years after randomization (P=0.89). Plasma BNP concentration was ≥200 pg/ml in 49 patients in the azosemide group and in 51 patients in the furosemide group. An increase in BNP by >30% of the value at randomization occurred in 11% in the azosemide group and 15% in the furosemide group at 1 year after randomization (P=0.75) and in 11% in the azosemide group and 15% in the furosemide group at 2 years after randomization (P=0.75).
Safety
Relevant adverse events are summarized in Table 5 . The incidence of hypotension, hypokalemia, digitalis intoxication or eruption did not differ between the 2 groups.
Discussion
We compared the effect of long-term administration of azosemide, a long-acting loop diuretic, to furosemide, a shortacting diuretic, on the prognosis in patients with CHF. The rate of the primary endpoint, a composite of cardiovascular death and unplanned admission to hospital for congestive HF, was significantly smaller in the azosemide group than in the Abbreviations see in Table 4 . Figure 3 . Subgroup analysis. Hazard ratios for cardiovascular death or unplanned admission to hospital for congestive heart failure (the primary endpoint) with furosemide vs. azosemide, according to subgroups. The subgroups are based on baseline demographic and clinical characteristics. The size of each square corresponds to the number of patients with an event. Data are missing for some patients in some subgroups. eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; LVDd, left ventricular end-diastolic dimension; AF, atrial fibrillation; AFL, atrial flutter; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin type 1 receptor blocker.
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furosemide group. The superiority of azosemide to furosemide was consistent across all subgroups. With azosemide, there was also a reduction in unplanned admissions to hospital for congestive HF or the need for modification of the treatment for HF. Adverse effects occurred equally in both groups. Azosemide and furosemide were equally safe in the treatment of CHF. The mechanisms by which azosemide provided a better prognosis than furosemide are not fully understood. Loop diuretics may be divided into short-and long-acting, and furosemide, a short-acting drug, is the most widely used. McCurley et al demonstrated that the acceleration of left ventricular dysfunction by furosemide was associated with an increase in plasma aldosterone level in a tachycardia-induced HF model. 11 Yoshida et al have shown that sympathetic activation might explain the lack of improvement in mortality for HF treatment with furosemide, despite the reduction in preload and afterload. 13 These experimental studies suggested that neurohumoral activation by short-acting loop diuretics partly explains the lack of improvement in mortality for patients treated with loop diuretics. Azosemide, a long-acting loop diuretic, induced diuresis without activating sympathetic nerves in a rat model of HF. 13 However, plasma norepinephrine levels 2 years after randomization were not different between the 2 groups. We did not collect blood samples after 30 min of bed rest nor did we request the patients to take diuretics in the morning of blood sampling. These sampling conditions might obscure differences between the 2 groups. Electrolyte or metabolic disturbances induced by loop diuretics could have deleterious effects on the prognosis on CHF. The incidence of hypokalemia was similar between the 2 groups. However, we did not evaluate serum levels of sodium, chloride, calcium, magnesium, glucose or lipids in this study. Azosemide might have different effects on these factors from furosemide. Further studies are needed.
Western readers might think the doses of loop diuretics were too low in this study. Japanese doctors usually hesitate to prescribe higher doses of loop diuretics because they frequently induce worsening of renal function and hyponatremia. In a recent post-hoc analysis of the Beta-Blocker Evaluation of Survival Trial study, blood urea nitrogen was less than 21 mg/dl in approximately one-third of the CHF patients who received high-dose loop diuretics (furosemide ≥160 mg/day). 21 If we prescribe such a high dose of loop diuretics in Japan, almost all the patients would show azotemia.
The incidence of worsening of symptoms and of an increase in plasma BNP by ≥30% of the value at randomization in patients with BNP ≥200 pg/ml at randomization did not differ between the azosemide and furosemide groups. This might be related to the reinforcement of the therapy in the subjects whose symptoms worsened.
Previous randomized or non-randomized observational studies have suggested the superiority of torasemide, a longacting loop diuretic, to furosemide. 17,22,23 Torasemide inhibits aldosterone binding to its receptor 24, 25 and several clinical studies have demonstrated the usefulness of aldosterone blockers in patients with HF. 26,27 Thus, it is unclear whether the benefits of torasemide are provided through its longer half-life or through an associated aldosterone blockade action. Our results indicate that the benefits of torasemide are provided at least partially through its longer half-life. Azosemide, which has a longer half-life and longer duration of action than torasemide, may be the first choice of loop diuretic in CHF treatment.
It is stated that "diuretics should always be administered in combination with angiotensin-converting enzyme (ACE)-inhibitors and β-blockers if tolerated" in the guideline from the European Society of Cardiology. 4 One might think combining the administration of ACE inhibitors/angiotensin-receptor blockers (ARBs) and/or β-blockers might prevent loop diuretic-induced neurohumoral activation. Long-acting loop diuretics were superior to short-acting loop diuretics even when ACE inhibitors or ARBs and β-blockers were administered in 226 (71%) and 166 (52%) of patients, respectively. Currently, we do not have data about the doses of the ACE inhibitors/ ARBs and β-blockers, and even if administered to most of the patients, the doses might have been too small to prevent loop diuretic-induced neurohumoral activation. Alternatively, the difference may not be explained solely by loop diuretic-induced neurohumoral activation and another mechanism should be considered.
We included in the study not only patients with HF and reduced EF but also those with HF with preserved EF (HFPEF). Regarding the etiologies of HF, "others" was the most frequent category. Enrollment of HFPEF patients might cause the lower prescription rates of ACE inhibitors/ARBs and β-blockers in J-MELODIC than in contemporary trials of CHF because these medicines have not been proven to be effective in HFPEF. When we compared the superiority of long-acting diuretics to short-acting diuretics between those with and without a reduced EF, there was no difference between the subsets.
Study Limitations
3 limitations of the study are noted. First, unplanned admission to hospital for congestive HF, part of the primary endpoint, depended on the subjective judgment of the admitting doctor. One might doubt that the superiority of azosemide to furosemide was caused by a bias of researchers toward azosemide because the current study used a PROBE design. However, unplanned admission to hospital for congestive HF or the need for modification of the treatment for HF, one of the secondary endpoints, was also reduced in the azosemide group, compared to the furosemide group. This finding suggests that intentional avoidance of admission was not the cause of the reduced number of primary endpoints in the azosemide group. Second, the number of patients was small and the incidence rate of the primary endpoint was low at 6.2%/year, which was much less than expected. The reasons for the low incidence rate of the primary endpoint were that patients with NYHA III symptoms at randomization comprised only 11% in this study and the rates of patients who received ACE inhibitors, ARB, and β-blockers were higher than in previous Japanese trials of CHF. 19,28, 29 The low incidence rate of the primary endpoint weakened the statistical power of this study, together with the small number of patients. All subset analyses were negative; however, we still need further studies to conclude that azosemide is better than furosemide for all types of CHF. Third, most patients were assumed to be taking furosemide before randomization because it is by far the most prescribed loop diuretic in Japan. Thus, most patients in the azosemide group needed dose adjustment of the newly prescribed medicine after randomization, whereas patients in the furosemide group did not. The difference in the ratio of patients who changed medicine at randomization could have affected the incidence of the endpoints. Fortunately, this might not be the case in this study because the numbers of endpoints were similar in both groups within 8 weeks after randomization.
Conclusion
Azosemide, compared to furosemide, reduced the risk of car-Long-Acting Loop Diuretic in Congestive HF diovascular death and unplanned admission to hospital for congestive HF. In spite of recent progress in the treatment of HF following a number of prospective clinical trials during the past decades, the prognosis of HF patients is still poor. 30 Switching short-acting diuretics to long-acting ones may improve the prognosis of patients with CHF.
